卢帅

来源:赵飞发布时间:2022-09-15浏览次数:1162

 

卢帅,男,2012年毕业于中国药科大学药物化学专业,获得理学博士学位,2013年进入中国药科大学理学院有机化学教研室工作至今,现为副教授。20163月至20173月在美国University of Minnesota著名药物化学家Gunda I. Georg课题组做国家公派访问学者。研究方向为小分子靶向抗肿瘤药物的设计与合成,以及利用CADDAI技术发现针对肿瘤、炎症等疾病的新分子实体。主持并参与多项国家自然科学基金、江苏省自然科学基金及中央高校基本科研业务费项目。在JMCEJMCJCIM等药物化学领域杂志上发表学术论文15篇以上,获得中国授权发明专利6项。在陆涛教授团队参与I抗急性髓性白血病临床候选药物FN-1501的研发,目前该药物已获得美国FDA的孤儿药资格认定。

电子邮箱lu_shuai@cpu.edu.cnluai071@163.com    手机:15851830954

地址:江苏省南京市江宁区龙眠大道639号中国药科大学实验楼C301 

代表性论著与授权专利:

1.Wang ZJ, Cai JH, Cheng J, Yang WQZ, Zhu YF, Li HM, Lu T*, Chen YD*, Lu S*. FLT3 inhibitors in acute myeloid leukemia: challenges and recent developments in overcoming resistance [J]. J. Med. Chem. 2021, 64 (6), 2878-2900.

2.Cui QJ#, Lu S#, Ni BW, Zeng X, Tan Y, Chen YD*, Zhao HP*. Improved prediction of aqueous solubility of novel compounds by going deeper with deep learning [J]. Front. Oncol. 2020, 10, 121.

3.Bao JY #, Liu HC #, Zhi YL, Yang WQZ, Zhang JW, Lu T, Wang Y *, Lu S *. Discovery of benzo[d]oxazole derivatives as the potent type-I FLT3-ITD inhibitors [J]. Bioorg. Chem. 2020, 94, 103248.

4.Heng H#, Wang ZJ#, Li HM#, Huang YT, Lan QY, Guo XX, Zhang L, Zhi YL, Cai JH, Qin TR, Xiang L, Wang SX, Chen YD*, Lu T, Lu S*. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model [J]. Eur. J. Med. Chem. 2019, 176, 248-267.

5.Ran T#, Li WJ#, Peng BL, Xie BL, Lu T, Lu S*, Liu W*. Virtual Screening with a Structure-Based Pharmacophore Model to Identify Small-Molecule Inhibitors of CARM1 [J]. J. Chem. Inf. Model. 2019, 59(1), 522-534.

6.Heng H#, Zhi YL#, Yuan HL#, Wang ZJ, Li HM, Wang SX, Tian JY, Liu HC, Chen YD, Lu T*, Ran T*, Lu S*. Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation [J]. Eur. J. Med. Chem. 2019, 163, 195-206.

7.Zhi YL, Li BQ, Yao C, Li HM, Chen PZ, Bao JY, Qin TR, Wang Y, Lu T*, Lu S*. Discovery of the selective and efficacious inhibitors of FLT3 mutations [J]. Eur. J. Med. Chem. 2018, 155, 303-315.

8.Wang, Y#, Zhi YL#, Jin QM, Lu S, Lin GW, Yuan HL, Yang TT, Wang ZW, Yao C, Ling J, Guo H, Li TH, Jin JL, Li BQ, Zhang L, Chen YD*, Lu T*. Discovery of 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), as a FLT3/CDKs kinase inhibitor with potential high efficiency against acute myelocytic leukemia (AML) [J]. J. Med. Chem. 2018, 61(4), 1499-1518.

9.Zhang F, Lu S, He JL, Jin HH, Wang FX, Wu L, Shao JJ, Chen AP, Zheng SZ*. Ligand Activation of PPARγ by Ligustrazine Suppresses Pericyte Functions of Hepatic Stellate Cells via SMRT-Mediated Transrepression of HIF-1α [J]. Theranostics. 2018, 8(3), 610-626.

10.Lan QY, Zhi YL, Heng H, Tian JY, Guo XX, Liu HC, Chen YD, Lu T*, Lu S*. Chemical Space of FLT3 Inhibitors as the Potential Anti-AML Drugs [J]. Recent Pat. Anticancer Drug Discov. 2017, 12(4), 296-322.

11.陆涛,卢帅,孔凯来,刘海春,陈亚东,高毅平,张陆勇,孙善亮芳香双酰肼类PLK1抑制剂及其用途 [P]. 中国,2015.1,专利号:ZL201110058119.0.

12.陆涛,朱雍,卢帅,张陆勇,陈亚东,焦宇RafHDAC小分子双重抑制剂及其制备和应用 [P].中国,2013.2,专利号:ZL200910028175.2.

13.卢帅,张亮,郭晓星,陆涛一种合成稠杂环化合物的方法 [P]. 中国,2016.3,专利号:ZL201310372812.4.

14.卢帅,张亮,刘海春,郭晓星,孙善亮,陈亚东,陆涛2-唑环取代噻吩类PLK1抑制剂及其用途 [P]. 中国,2016.5,专利号:ZL201310372834.0.

15.卢帅,金乔梅,王越,陈亚东,陆涛4-(稠杂环取代氨基)-1H-吡唑-3-甲酰胺类化合物及其用途 [P]. 中国,2019.10,专利申请号:ZL201510040717.3. 2019.10.01授权(转让于复星医药)

16.卢帅,王越,支燕乐,尧超,陆涛,李保泉,陈璞洲,鲍吉银,4-(芳杂环取代)氨基-1H-3-吡唑甲酰胺类FLT3抑制剂及其用途[P]. 中国,2020.4,专利号:ZL201710567840.X.